First-dose and steady-state pharmacokinetics of orally administered crizotinib in children with solid tumors: a report on ADVL0912 from the Children’s Oncology Group Phase 1/Pilot Consortium

Cancer Chemotherapy and Pharmacology

Volumn 79, Issue 1, 2017, Pages 181-187

  Balis, Frank M ^a   Thompson, Patrick A ^b   Mosse, Yael P ^a   Blaney, Susan M ^c   Minard, Charles G ^c   Weigel, Brenda J ^d,e   Fox, Elizabeth ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e The Children s Oncology Group Operations Center   (United States)

Author keywords

ALK; Childhood cancer; Children; Crizotinib; Pharmacokinetics

Indexed keywords

CRIZOTINIB; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ACCUMULATION INDEX; ADOLESCENT; ADULT; ANAPLASTIC LARGE CELL LYMPHOMA; AREA UNDER THE CURVE RATIO; ARTICLE; CHILD; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG FORMULATION; DRUG HALF LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; PHARMACOKINETIC PARAMETERS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SOLID TUMOR; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; CLINICAL TRIAL; LYMPHOMA, LARGE-CELL, ANAPLASTIC; NEOPLASMS; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRESCHOOL CHILD;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MALE; NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES;

EID: 85007467216     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-016-3220-6     Document Type: Article

References (11)

1. Frampton JE (2013) Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer. Drugs 73(18):2031–2051. doi:10.1007/s40265-013-0142-z
2. Cappuzzo F, Moro-Sibilot D, Gautschi O, Boleti E, Felip E, Groen HJ, Germonpre P, Meldgaard P, Arriola E, Steele N, Fox J, Schnell P, Engelsberg A, Wolf J (2015) Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus. Lung Cancer 87(2):89–95. doi:10.1016/j.lungcan.2014.12.010
3. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F (2014) First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371(23):2167–2177. doi:10.1056/NEJMoa1408440
4. Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, Riely GJ, Solomon B, Ou SH, Kim DW, Salgia R, Fidias P, Engelman JA, Gandhi L, Janne PA, Costa DB, Shapiro GI, Lorusso P, Ruffner K, Stephenson P, Tang Y, Wilner K, Clark JW, Shaw AT (2012) Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 13(10):1011–1019. doi:10.1016/S1470-2045(12)70344-3
5. Gambacorti-Passerini C, Messa C, Pogliani EM (2011) Crizotinib in anaplastic large-cell lymphoma. N Engl J Med 364(8):775–776. doi:10.1056/NEJMc1013224
6. Mosse YP, Lim MS, Voss SD, Wilner K, Ruffner K, Laliberte J, Rolland D, Balis FM, Maris JM, Weigel BJ, Ingle AM, Ahern C, Adamson PC, Blaney SM (2013) Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children’s Oncology Group phase 1 consortium study. Lancet Oncol 14(6):472–480. doi:10.1016/S1470-2045(13)70095-0
7. Murga-Zamalloa C, Lim MS (2014) ALK-driven tumors and targeted therapy: focus on crizotinib. Pharmacogenomics Pers Med 7:87–94. doi:10.2147/PGPM.S37504
8. Xu H, O’Gorman M, Boutros T, Brega N, Kantaridis C, Tan W, Bello A (2015) Evaluation of crizotinib absolute bioavailability, the bioequivalence of three oral formulations, and the effect of food on crizotinib pharmacokinetics in healthy subjects. J Clin Pharmacol 55(1):104–113. doi:10.1002/jcph.356
9. Hamilton G, Rath B, Burghuber O (2015) Pharmacokinetics of crizotinib in NSCLC patients. Expert Opin Drug Metab Toxicol 11(5):835–842. doi:10.1517/17425255.2015.1021685
10. Christensen JG, Zou HY, Arango ME, Li Q, Lee JH, McDonnell SR, Yamazaki S, Alton GR, Mroczkowski B, Los G (2007) Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 6(12 Pt 1):3314–3322. doi:10.1158/1535-7163.MCT-07-0365
11. Johnson TR, Tan W, Goulet L, Smith EB, Yamazaki S, Walker GS, O’Gorman MT, Bedarida G, Zou HY, Christensen JG, Nguyen LN, Shen Z, Dalvie D, Bello A, Smith BJ (2015) Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects. Xenobiotica 45(1):45–59. doi:10.3109/00498254.2014.941964